CorMedix Inc.
CRMD
NASDAQ·Healthcare·Biotechnology·Mkt cap $661.3M
$8.43
▼ -0.47%
P/E
3.81
Mkt Cap
$661.3M
52-Wk Range
$6.13–$13.83
52-Week Range
$6.13 - $13.83
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 33.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary DefenCath/Neutrolin technology with novel anti-infective mechanism
- Focused expertise in catheter-related infection prevention addressing large unmet medical need
- Specialized development in high-value clinical settings with limited competitive alternatives
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Revenue decline expected
Increasing prevalence of central venous catheter use in hemodialysis and oncology
Value
Trading at 0.8x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Stable
-1.3% over 3m
Quality
Excellent
High-growth business (281% revenue growth, 83% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying CRMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of $0.29 vs $0.24 consensus (+21.9% surprise). Revenue of $101.9M vs $96.0M expected (+6.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+21.9%
Revenue trend · last 8Q
—
—
—
—
+810%
+312%
+226%
+157%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$11.5M
$31.2M
$39.1M
$39.7M
$104.3M
$128.6M
$127.4M
$101.9M
Margins · last 8Q
Gross
75.7%
Operating
42.1%
Profit
25.5%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citizens · Apr 28, 2026
vs Industry
How CRMD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related